UNEEG Medical

UNEEG Medical

Ballerup, Denmark· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $12.5M

Overview

UNEEG Medical is a commercial-stage neurotechnology company based in Denmark, focused on transforming epilepsy care through its implantable, subcutaneous EEG monitoring platform. Its CE-marked UNEEG EpiSight System captures continuous brain data for up to three years, addressing diagnostic uncertainties and enabling objective treatment assessment via proprietary AI analytics. The company is executing its European commercialization strategy and preparing for a U.S. market launch, positioning its longitudinal data as a valuable asset for clinical decision-making and pharmaceutical R&D.

EpilepsySleep Disorders

Technology Platform

Implantable subcutaneous EEG (sEEG) monitoring system with external recorder, patient app, and cloud-based AI analytics software for ultra-long-term, real-world brain data collection and analysis.

Funding History

2
Total raised:$12.5M
Series A$12M
Grant$500K

Opportunities

The large population of drug-resistant epilepsy patients creates a direct market for improved monitoring.
The aggregated longitudinal EEG database presents a significant opportunity to partner with pharmaceutical companies for clinical trial endpoints and digital biomarker development, creating a high-margin data-as-a-service revenue stream.

Risk Factors

Key risks include the uncertainty and cost of obtaining FDA clearance for U.S.
market entry, challenges in securing adequate reimbursement from healthcare payers for a novel chronic monitoring system, and slower-than-expected adoption by neurologists due to workflow integration hurdles.

Competitive Landscape

UNEEG competes with traditional inpatient video-EEG monitoring, short-term ambulatory EEG devices, and emerging wearable neuro-sensing technologies. Its primary differentiation is the multi-year, subcutaneous form factor enabling truly longitudinal data. Potential competitors include large medtech firms with neuromodulation portfolios and digital health startups focusing on seizure detection.